SLN (Silence Therapeutics) Net Issuance of Debt : $-0.24 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Silence Therapeutics's net issuance of debt for the three months ended in Sep. 2024 was $-0.07 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.24 Mil.

Silence Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Silence Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Net Issuance of Debt Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

-0.54

-0.28

-0.23

-0.22

Silence Therapeutics Quarterly Data
	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Issuance of Debt	Get a 7-Day Free Trial															-0.06	-0.05	-	-0.12	-0.07

Silence Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.

Silence Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.